- Home
- GOSS vs DHF Comparison
GOSS vs DHF Comparison
Compare GOSS & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DHF
- Stock Information
- Founded
- GOSS 2015
- DHF 1998
- Country
- GOSS United States
- DHF United States
- Employees
- GOSS N/A
- DHF N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- GOSS Health Care
- DHF Finance
- Exchange
- GOSS Nasdaq
- DHF Nasdaq
- Market Cap
- GOSS 212.9M
- DHF 187.7M
- IPO Year
- GOSS 2019
- DHF N/A
- Fundamental
- Price
- GOSS $0.80
- DHF $2.54
- Analyst Decision
- GOSS Strong Buy
- DHF
- Analyst Count
- GOSS 5
- DHF 0
- Target Price
- GOSS $9.20
- DHF N/A
- AVG Volume (30 Days)
- GOSS 2.3M
- DHF 451.1K
- Earning Date
- GOSS 11-07-2024
- DHF 01-01-0001
- Dividend Yield
- GOSS N/A
- DHF 7.65%
- EPS Growth
- GOSS N/A
- DHF N/A
- EPS
- GOSS N/A
- DHF N/A
- Revenue
- GOSS $105,322,000.00
- DHF N/A
- Revenue This Year
- GOSS N/A
- DHF N/A
- Revenue Next Year
- GOSS N/A
- DHF N/A
- P/E Ratio
- GOSS N/A
- DHF N/A
- Revenue Growth
- GOSS N/A
- DHF N/A
- 52 Week Low
- GOSS $0.50
- DHF $2.06
- 52 Week High
- GOSS $1.60
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- GOSS 50.75
- DHF 35.38
- Support Level
- GOSS $0.83
- DHF $2.62
- Resistance Level
- GOSS $1.10
- DHF $2.62
- Average True Range (ATR)
- GOSS 0.08
- DHF 0.03
- MACD
- GOSS 0.02
- DHF -0.01
- Stochastic Oscillator
- GOSS 31.66
- DHF 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.